AstraZeneca Pharma receives CDSCO nod for expanded use of Fasenra in India
AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Benralizumab (brand name: Fasenra) in India for an additional medical indication.
The newly approved indication allows Fasenra to be used as an add-on treatment for adult patients suffering from relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This rare autoimmune condition is known to cause inflammation of blood vessels, leading to organ damage.
AstraZeneca confirmed the development in a regulatory filing to the stock exchanges on May 29, 2025, under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements.
The company stated that while the permission paves the way for marketing Fasenra in India for the newly approved indication, it remains subject to receipt of additional statutory clearances if required.
Fasenra is already approved in India for other eosinophilic conditions, and this marks an important expansion in its therapeutic scope, potentially benefiting more patients with complex immunological diseases.
'The receipt of this permission paves way for the marketing of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) in India for the specified additional indication,' the company noted in the filing.
The company secretary Manasa R signed off the communication to both BSE and NSE.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
a day ago
- Business Upturn
Why are Indoco Remedies shares up 2% today? Explained
By Aditya Bhagchandani Published on August 13, 2025, 10:05 IST Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban tablets, a generic version of Bayer's blockbuster anticoagulant Xarelto. The approval covers multiple dosage strengths — 2.5 mg, 10 mg, 15 mg, and 20 mg — positioning Indoco to tap into the lucrative US market for blood thinners, which has significant demand due to rising cardiovascular cases. Industry data shows Rivaroxaban sales in the US crossed $2 billion in recent years. Indoco said the launch will be executed through its marketing partner in the US, adding that this development strengthens its complex generics portfolio and enhances its revenue visibility in the American market. The stock's rally reflects investor optimism about the earnings potential from this launch, given that US generics typically offer higher margins than domestic formulations. Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in equities involves risks. Please consult a certified financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
a day ago
- Business Upturn
NHPC shares edge up 2% after Q1 profit rises 3% on higher income
By Aditya Bhagchandani Published on August 13, 2025, 09:55 IST NHPC Ltd shares rose nearly 2% in early trade on Wednesday, August 13, after the state-owned hydropower major reported a modest rise in its June quarter earnings, backed by higher income and fresh capacity additions. The stock opened firm at ₹83.91 and climbed to ₹85.86 during the session, trading at ₹85.56, up 1.97%, with a market cap of ₹858.35 crore. Q1 FY26 Earnings Snapshot For the quarter ended June 30, 2025, NHPC posted a net profit of ₹1,131.16 crore, up 3% from ₹1,101.63 crore in the same quarter last year. The increase was driven by a 13% jump in total income to ₹3,442.76 crore, compared with ₹3,037.92 crore a year earlier. The state-run utility also commissioned the 800 MW Parbati-II Project during the quarter, further expanding its operational capacity. Additionally, it brought online 214.28 MW out of the 300 MW Kamisar Solar Power Project in Bikaner, reflecting its growing footprint in renewable energy beyond hydro. Operational Highlights Hydropower Focus: NHPC continues to be India's largest hydropower development organisation under the Ministry of Power, with capabilities spanning conception to commissioning of hydro projects. Renewables Expansion: The company is steadily diversifying into solar and wind energy, complementing its hydro portfolio. Strategic Additions: Capacity expansions this quarter align with the government's renewable push and NHPC's long-term growth strategy. Market Reaction Investor sentiment was buoyed by the revenue growth and commissioning of new projects, although the profit growth remained modest. Analysts see NHPC's expansion into solar as a positive long-term catalyst, but the near-term earnings trajectory will depend on seasonal power demand and execution timelines for under-construction projects. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
